Abstract
This study explored the feasibility and toxicity of individualized toxicity‐titrated 6‐mercaptopurine (6MP) dose increments during post‐remission treatment with High‐dose methotrexate (HDM) (5000 mg/m2, ×3) in 38 patients with Childhood (ALL). Patients were increased in steps of 25 mg 6MP/m2 per day if they did not develop myelotoxicity within 2 weeks after HDM. 6MP could be increased in 31 patients (81%). Toxicity was acceptable and did not differ significantly between groups. Patients receiving 75 mg/m2 per day had significantly shorter duration of treatment interruptions of 6MP than the remaining patients (P = 0·03). This study shows individualized toxicity‐titrated 6MP dosing during consolidation is feasible without increased risk of toxicity.
Original language | English |
---|---|
Journal | British Journal of Haematology |
Volume | 155 |
Issue number | 2 |
Pages (from-to) | 244-247 |
ISSN | 0007-1048 |
DOIs | |
Publication status | Published - 2011 |
Externally published | Yes |
Keywords
- Acute lymphoblastic leukaemia
- Chemotherapy
- Children
- Consolidation
- Purine analogues